Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ...

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, announced today that the ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS) has recently completed a clinical study titled ‘A Feasibility of Neoadjuvant Interstitial ...

Alpha Tau Medical Ltd. announced significant advancements in their alpha-radiation cancer treatment, Alpha DaRT®, during the 2025 ASCO GI Symposium and R&D Update Day. Interim results from three ...

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients ...

Alpha Tau Medical Ltd. (NASDAQ: DRTS) shares climbed 25.26% in after-hours trading to $5.30, after the company announced the first patient treatment in its pilot study for recurrent glioblastoma ...

The U.S. Department of Health and Human Services will start a study on cellphone radiation, a department spokesman said on Thursday.

Alpha Tau Medical Ltd. announced that it has achieved Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem, which is a key step in ensuring quality, ...

Alpha particle radioluminescence detection and imaging is an advanced optical technique that capitalises on the light emitted when alpha particles interact with air molecules. When alpha particles – ...